Vitrolife ABOSTO:VITR +0.11%78 Net Margin % is 12.52% as of Mar. 2026, which is 41% below its 10-year median of 21.27. GuruFocus rates OSTO:VITR with a GF Score™ of 78/100 and a GF Value™ of kr162.15 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 817 Medical Devices & Instruments companies, Vitrolife AB ranks worse than 85.31% on this metric.
Net margin is calculated as Net Income divided by its Revenue. Vitrolife AB's Net Income for the
three
months ended in Mar. 2026 was kr101 Mil. Vitrolife AB's Revenue for the
three
months ended in Mar. 2026 was kr807 Mil. Therefore, Vitrolife AB's net margin for the quarter that ended in Mar. 2026 was 12.52%.
The historical rank and industry rank for Vitrolife AB's Net Margin % or its related term are showing as below:
OSTO:VITR'
s Net Margin % Range Over the Past 10 Years
Min: -147.21 Med: 21.27 Max: 26.9
Current: -147.21
OSTO:VITR's Net Margin % is ranked worse than 85.31% of 817
companies
in the Medical Devices & Instruments industry
Industry Median: 2.09
vs OSTO:VITR: -147.21
Vitrolife AB (OSTO:VITR) Net Margin % Explanation
Although Net Income and Earnings-per-Share (EPS) are the most widely used parameter in measuring a company's profitability and valuation, it is the least reliable. The reason is that reported earnings can be manipulated easily by adjusting any numbers such as Depreciation, Depletion and Amotorization and non-recurring items.
But the long term trend of the net margin is a good indicator of the competitiveness and health of the business.
Vitrolife AB Net Margin % Related Terms
Vitrolife AB Net Margin % Historical Data
* Premium members only.
The historical data trend for Vitrolife AB's Net Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
OSTO:VITR vs ABT, SYK, MDT: Net Margin % Comparison
For the Medical Devices subindustry, Vitrolife AB's Net Margin %, along with its competitors' market caps and Net Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Vitrolife AB Net Margin % vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, Vitrolife AB's Net Margin % distribution charts can be found below:
* The bar in red indicates where Vitrolife AB's Net Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Vitrolife AB (OSTO:VITR) has a Net Margin % of 12.52% as of Mar. 2026. Net margin is the ratio of total net income to net sales. View historical data on Vitrolife AB and its competitors. This is 41% below median its historical median of 21.27. According to the industry distribution chart, Vitrolife AB ranks #697 out of 817 companies in the Medical Devices & Instruments industry, placing it in the top 85.3%.
Is Vitrolife AB's Net Margin % too high?
Vitrolife AB's current Net Margin % of 12.52% is 41% below median its 10-year median of 21.27. The Medical Devices & Instruments industry median Net Margin % is 2.09. Vitrolife AB's value of 12.52% is 499% above this industry median. Based on the distribution chart, Vitrolife AB ranks #697 out of 817 companies in the Medical Devices & Instruments industry, which is in the bottom quartile relative to peers. Overall, Vitrolife AB has a GF Score™ of 78/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Vitrolife AB's Net Margin % compare to ABT and SYK?
According to the Medical Devices & Instruments industry distribution chart, Vitrolife AB ranks #697 out of 817 companies for Net Margin %. This places Vitrolife AB in the lower half of its industry. The industry median Net Margin % is 2.09. Vitrolife AB's value of 12.52% is 499% above this benchmark. While the company's 10-year median is 21.27 vs. the industry median of 2.09, Vitrolife AB has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Net Margin % for a Medical Devices & Instruments company?
The median Net Margin % among Medical Devices & Instruments companies is 2.09, based on 817 companies in the industry. Companies in the top quartile (top 25%) have a Net Margin % significantly above this median, while those in the bottom quartile fall well below. However, Net Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Vitrolife AB's current Net Margin % of 12.52% is 499% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Net Margin % mean?
A high Net Margin % can signal that a stock is expensive relative to its fundamentals. Net margin is the ratio of total net income to net sales. View historical data on Vitrolife AB and its competitors. For the Medical Devices & Instruments industry, the median Net Margin % is 2.09 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Vitrolife AB's current Net Margin % is 12.52%, which is 41% below median its own 10-year median of 21.27. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Vitrolife AB stock overvalued right now?
Based on GuruFocus' analysis, Vitrolife AB (OSTO:VITR) is currently considered Possible Value Trap. The stock's GF Value™ is kr162.15, compared to a current price of kr89.65 — trading 44.7% below its estimated fair value. The current Net Margin % is 12.52%, which is 41% below median its 10-year median of 21.27 and 499% above the Medical Devices & Instruments industry median of 2.09. Vitrolife AB's overall GF Score™ is 78/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Net Margin % calculated?
Net Margin % is calculated from a company's financial statements. For Vitrolife AB (OSTO:VITR), the current Net Margin % is 12.52% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Vitrolife AB (OSTO:VITR) Overvalued in 2026?
Based on GuruFocus' analysis, Vitrolife AB stock appears to be undervalued.
The current stock price of kr89.65 is trading 44.7% below its estimated GF Value™ of kr162.15.
GuruFocus considers Vitrolife AB to be Possible Value Trap.
Key valuation signals for OSTO:VITR:
Net Margin %: 12.52% (41% below median its 10-year median of 21.27)
GF Value™: kr162.15 vs. price of kr89.65 (44.7% below fair value)
Industry Position: 499% above the Medical Devices & Instruments median (#697 of 817)
No single metric tells the full story. See the OSTO:VITR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Vitrolife AB provides medical devices and genetic testing services intended for the reproductive-health market in the field of reproductive health. The company develops, manufactures, and distributes medical devices and provides genetic testing services for IVF clinics and their patients. Its mission is to support IVF clinics (in vitro fertilization) in enhancing their practice as well as the outcome of a patient's fertility treatment, thereby enabling patients to receive support to navigate the complexities of reproductive health through successful outcomes and patient satisfaction. The company has three geographical segments EMEA, Americas and APAC, out of which it derives maximum revenue from EMEA.
78GF Score
Get the complete analysis for OSTO:VITR
Net Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
OSTO:VITR has been successfully added to your 
